Aurobindo Pharma Q4FY26: Profit up 2%, margins slip

Key takeaway from the March-quarter print

Aurobindo Pharma reported a modest improvement in earnings for Q4FY26, helped by strong growth in Europe and other markets even as its US business remained weak. Net profit for the March quarter rose 2% year-on-year to Rs 921 crore, while consolidated revenue increased 5.6% to Rs 8,853 crore. The quarter, however, was marked by margin pressure. EBITDA rose only 0.5% to Rs 1,801 crore, and EBITDA margin declined to 20.3%, down from 21.4% a year earlier.

What stood out: Europe and growth markets did the heavy lifting

The company’s regional mix played a central role in supporting headline growth. Europe revenues surged 30.2% YoY to Rs 2,795 crore, emerging as the key driver in the quarter. Growth markets rose 24.7% YoY to Rs 980 crore, adding to momentum outside the US.

At the same time, management commentary in the results indicated that weakness in the US business continued to weigh on the overall performance. While the company did not provide a US revenue number in the provided data for Q4FY26, it attributed subdued earnings growth to weaker US performance alongside higher operating costs and some foreign exchange-related impact.

Profit growth remained muted despite higher revenue

Even with a healthy top-line increase, profitability did not expand at the same pace. The company’s EBITDA growth was nearly flat, signalling that cost pressures and mix likely offset some of the benefit from higher sales. The reported margin decline to 20.3% indicates that operating leverage did not fully play out in the quarter.

The company also pointed to some offsets to these pressures. It said the impact of higher operating costs and forex-related factors was partially offset by lower finance costs and stable gross margins. That combination helped prevent a sharper decline in profitability even as operating metrics softened.

Full-year profitability: limited growth flagged in the update

Along with the quarterly update, the provided information also noted that net profit increased 0.6% to Rs 3,503 crore, reflecting continuing pressure on profitability. The same commentary attributed the subdued earnings growth to the US performance, higher operating costs, and forex-related impact, partially mitigated by lower finance costs and stable gross margins.

Separately, the provided text also included FY25 numbers: for the full financial year, Aurobindo Pharma reported revenue from operations of Rs 31,724 crore and net profit rising 9.9% YoY to Rs 3,484 crore. These FY25 figures provide context on the company’s scale and longer-term profit trajectory ahead of the FY26 quarterly print.

How Q4FY26 compares with Q4FY25 numbers in the record

The dataset also includes a detailed snapshot of Q4FY25, which helps frame the year-on-year comparison for margins and profitability. In Q4FY25, Aurobindo Pharma reported a 0.5% YoY decline in net profit to around Rs 903 crore (figures in the text range between Rs 903 crore and Rs 903.5 crore), while revenue from operations grew 10.5% YoY to Rs 8,382.1 crore. EBITDA in Q4FY25 was cited at Rs 1,792 crore with a 21.4% margin.

That earlier quarter also showed stronger US momentum on a year-on-year basis, with US formulation revenue up 13.5% YoY to Rs 4,072 crore, and Europe formulation revenue up 17.2% YoY to Rs 2,147 crore. In contrast, growth market formulation revenue declined 7.8% YoY to Rs 786 crore, and domestic formulation sales were Rs 56 crore.

Snapshot table: Q4FY26 vs Q4FY25 (as stated)

Market impact: what the numbers signal for investors

The main market-relevant signal from the Q4FY26 print is the divergence between revenue growth and profit growth. A 5.6% rise in quarterly revenue alongside marginal EBITDA growth suggests that the cost base increased faster than sales, or that product and geography mix was less supportive of margins. The decline in EBITDA margin to 20.3% from 21.4% a year earlier quantifies this pressure.

The second signal is geographic dependence. Europe’s 30.2% growth to Rs 2,795 crore and growth markets’ 24.7% rise to Rs 980 crore helped cushion the drag from the US business. If this mix sustains, it can reduce over-reliance on the US cycle, but the quarter also shows that margin outcomes still depend heavily on operating costs and currency movement.

Background: FY25 context on volumes, regions, and balance sheet

The provided material includes additional FY25 operational context. Aurobindo Pharma described Q4FY25 as a record quarter with revenue of Rs 8,382 crore and EBITDA of Rs 1,792 crore at a 21.4% margin. It also mentioned US revenue of $170 million (48.6% of consolidated revenue) and 9 new ANDA filings in that period.

The same FY25 update referenced a balance-sheet improvement to a net cash position of $12 million, from net debt of $14 million in December 2024. While these figures are in foreign currency and relate to an earlier period, they provide a reference point on how management has positioned the company financially while dealing with shifting regional growth and operating cost trends.

What to watch next

Aurobindo Pharma’s Q4FY26 results reinforce two themes: Europe and growth markets are currently key growth engines, and margins remain sensitive to operating costs and forex movement. With profit growth lagging revenue growth, investors are likely to track whether margin pressure eases and how quickly the US business stabilises.

Future updates from the company on regional performance, cost trends, and finance costs will be important to assess whether earnings growth can re-accelerate after this quarter of modest profit expansion.